Guided Therapeutics (GTHP) Current Deferred Revenue (2010 - 2026)

Guided Therapeutics has disclosed Current Deferred Revenue across 17 years of filings, most recently posting $189000.0 for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 72.18% year-over-year to $189000.0; the TTM figure through Jun 2026 stood at $189000.0 (down 72.18% YoY), while the FY2025 annual figure was $189000.0, down 77.74% from the prior year.
• Current Deferred Revenue came in at $189000.0 for Q2 2026 at Guided Therapeutics, roughly flat from $189000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $514.0 million in Q1 2022 to a low of $189000.0 in Q4 2025.
• Average Current Deferred Revenue over 5 years is $29.1 million, with a median of $511050.5 recorded in 2022.
• Year-over-year, Current Deferred Revenue jumped 828932.26% in 2022 and plunged 99.91% in 2023.
• Over 5 years, Current Deferred Revenue stood at $509101.0 in 2022, then slipped by 16.67% to $424225.0 in 2023, then surged by 100.13% to $849000.0 in 2024, then tumbled by 77.74% to $189000.0 in 2025, then changed by 0.0% to $189000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $189000.0 in Q2 2026, $189000.0 in Q1 2026, and $189000.0 in Q4 2025.